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Osteonectin is a bone- associated protein involved in vascular calcification. Adiponectin may protect against 
cardiovascular disease but possible effects on vascular calcification have been poorly studied. The aim of this 
study was to investigate the modulatory effect of adiponectin on oxidized low density lipoprotein (oxLDL)- 
induced expression of osteonectin in human aorta vascular smooth muscle cells (HA/VSMCs). HA/VSMCs were 
cultured in F12K media and then treated with oxLDL (100 µg/mL) in the presence or absence of adoponectin (5 
µg/mL) for 24 and 48 hours. mRNA expression and protein level of osteonectin were determined by quantitative 
real-time PCR and western blot analysis, respectively. After exposure to oxLDL, osteonectin expression 
increased 1.62 ± 0.23- and 6.62 ± 0.48-fold after 24 and 48 hours respectively compared to the control. 
Adiponectin increased oxLDL- induced osteonectin expression in a time-dependent manner after 24 and 48 
hours (3.24 ± 0.39- and 24.93 ± 2.15-fold, respectively). Western blotting confirmed that osteonectin protein was 
upregulated by adiponectin.Our data suggest that OxLDL might cause the increase of osteonectin expression 
both at mRNA and protein level. This upregulation is intensified by adiponectin. 
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therosclerosis is a disorder characterized by 
the presence of atherosclerotic plaques in the 
arterial intima that leads to luminal narrowing (1, 
2). Calcification is a common event that occurs in 
the early phase of arteriosclerosis (3, 4) which is 
predisposing to coronary artery damage after 
angioplasty (5). Calcification reduces the blood 
walls elasticity that can lead to other cardiovascular 
problems (6). Oxidized low density lipoprotein 
(OxLDL) has been postulated to play an important 
role in foam cells formation and its accumula- 
tion in the vascular wall which stimulates the  
development of atherosclerosis and vascular 
calcification (7). 
Osteonectin, also known as secreted protein 
acidic and rich in cysteine (SPARC) is an 
extracellular matrix protein expressed in active 
remodeling in the skeleton and other tissues (8). 
A
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As with other bone-related proteins, osteonectin is 
expressed in the arterial wall during atherosclerosis 
progress specifically during calcification of the 
atherosclerotic plaque (9-11). 
Adiponectin is one of the adipocytokines 
released only from adipose tissue, which protects 
from the development and progression of athero-
sclerosis via anti- inflammatory effects. Decreased 
plasma adiponectin concentrations were reported in 
patients with coronary artery disease (12). Experi-
mental studies have shown that adiponectin has 
potential antiatherogenic characteristics (12, 13). 
Several experimental findings suggest that 
adiponectin may protect against cardiovascular 
inflammation (14, 15), but the possible effects of 
adiponectin on vascular calcification have not been 
fully investigated. Adiponectin probably reduces 
calcification process and therefore can be effective 
on reducing the risk of atherosclerosis (16-19). The 
aim of the present study was to investigate the 
effect of adiponectin on osteonectin expression in 
vascular smooth muscle cells (VSMCs) treated with 
oxLDL. 
 
Materials and methods 
Cell culture 
In this experimental study, human aorta 
vascular smooth muscle cells (HA/VSMCs) were 
cultured  in F12K media containing 0.05 mg/mL 
ascorbic acid, 0.01 mg/mL insulin, 0.01 mg/mL 
transferrin, 10 ng/mL sodium selenite, 0.03 mg/mL 
endothelial cell growth supplement, 10% FBS (final 
concentration), 10 mM 4-(2-hydroxyethyl) pipe-
razine-1-ethanesulfonic acid solution (HEPES), 10 
mM N-tris (hydroxymethyl) methyl-2-aminoethan-
esulfonic acid (TES), 100 U/mL penicillin, 100µg 
/mL streptomycin, and 0.01% amphotericin B. 
Cells were incubated in the humidified incubator  
at 37 °C with 5% CO2. Cells were used at passa-
ges 3-7. 
Cells were seeded in a 12- well cluster plates 
at a density of 10000 cells per well. When the cells 
achieved approximately 80% confluence, they were 
treated with either 100 µg/mL oxLDL (Biomedical 
Technologies Stoughton, MA, USA) or a combi-
nation of oxLDL and 5 µg/ mL adiponectin (Bio-
vendor, Heidelberg, Germany) in the presence of 10 
mM β-glycerophosphate. Cells without any treat-
ment were used as control. 
RNA isolation and cDNA synthesis 
Total RNA was extracted from the cells using 
Biozol RNA extraction reagent (Bioflux, Japan) 
after 24 and 48 hours. The RNA was quantified 
using a nanodrop  spectrophotometer (Thermo 
Fisher Scientific, USA) at 260 nm. The cDNA was 
synthesized from 0.3 µg total RNA using the Revert 
Aid First Standard cDNA Synthesis kit (Thermo 
Fisher Scientific ,Waltham, USA). 
Real-time polymerase chain reaction (PCR) 
Real- time PCR was performed using Rotor-
Gene 3000 real-time DNA amplification system 
(Corbett Research, Australia) and SYBR green 
method. Primers used for real-time PCR are listed 
in Table 1. Experiments were performed in 
triplicate. Each multiplex reaction mix (25 µl) 
contained 12.5 µl of SYBR Green PCR Master Mix 
(Qiagen, Valencia, USA), 0.3 µl of each primer (10 
µM), 3 µl cDNA (20 ng), and 8.9 µl nuclease-free 
water. The amplification was carried out under the 
following conditions: initial denaturing at 94 °C for 
5 minutes, then 40 cycles of 95 °C for 15 seconds, 
59 °C for 20 seconds and 72 °C for 30 seconds. 
Quantitation of data was performed using the 
comparative CT (∆∆CT) method, using glyceralde-
hyde 3-phosphate dehydrogenase gene expression 
as an endogenous reference. 
Western blot 
Cells were washed twice with cold phosphate 
buffered saline (PBS) and were lysed in ice-cold 2X 
radio- immune precipitation assay (RIPA) buffer. 
The homogenate was incubated in lysis buffer for 
30 minutes and then centrifuged at 12000 rpm for 
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Fig. 1. The effect of oxLDL and adiponectin on osteonectin gene expression in HA/VSMCs after 24 hours. (A) Osteonectin mRNA 
expression against control after treatment with oxLDL alone or together with adiponectin using real time PCR. Data have been expressed as 
means ± SEM for the three experiments. P values are indicated above the bars: ** P < 0.05, *** P < 0.01. (B) Western blot analysis showing 
osteonectin protein level after 24 hours of treatment with oxLDL alone or together with adiponectin. Beta-actin (42 kDa) was used as an 
internal control to standardize the protein loading in western blotting. 
10 minutes. The supernatant was used as total cell 
lysate. Protein concentration was measured spectro-
photometrically by Nanodrop at 280 nm and equal 
amounts of protein from each sample were 
subjected to blotting. Protein lysate was mixed with 
SDS loading buffer (Tris-HCl 0.125 M, SDS 4%, 
Glycine 20%, 2-Mercaptoethanol 10%), followed 
by boiling for 5 min, and separated by 12% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. 
The separated proteins were then transferred to a 
polyvinylidene difluoride membrane (PVDF) in 
tris-glycine buffer for 2 hours at 120 V. 
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Table 1. Primer sequences and amplicon length 
Genes Primer sequences (5'–3') Amplicon 
length (bp) 
Gene bank reference 
sequence 
Osteonectin Forward: TCTTCCCTGTACACTGGCAGTTC 
Reverse: AGCTCGGTGTGGGAGAGGTA 73 NM-003118.3 
GAPDH* Forward: ACACCCACTCCTCCACCTTTG 
Reverse: TCCACCACCCTGTTGCTGTAG 
112 NM-002046.5 
* Glyceraldehyde 3-phosphate dehydrogenase 
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Fig. 2. The effect of oxLDL and adiponectin on osteonectin gene expression in HA/VSMCs after 48 hours. (A) Osteonectin mRNA 
expression against control after treatment with oxLDL alone or together with adiponectin using real time PCR. Data have been expressed as 
means ± SEM for the three experiments. P values are indicated above the bars: **P < 0.05, ***P < 0.01. (B) Western blot analysis showing 
osteonectin protein level after 48 hours of treatment with oxLDL alone or together with adiponectin. Beta-actin (42 kDa) was used as an 
internal control to standardize the protein loading in western blotting 
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The membrane was blocked by 5% nonfat dry 
milk in tris-buffered saline, 0.1% tween-20 (TSBT) 
overnight at 4 °C temperature. Then, the membrane 
was incubated in TSBT containing 5 µg/ mL rabbit 
polyclonal anti osteonectin antibody (Abcam, 
Cambridge, UK) for 2 hours at room temperature. 
After washing, the membrane was incubated with 
horseradish peroxidase conjugated goat anti- rabbit 
IgG (Abcam, Cambridge, UK) diluted 1:10000 for 
90 minutes at room temperature. Finally, the color 
was developed with the addition of 3,3',5,5'-tetra-
methylbenzidine membrane peroxidase substrate 
(Roche, Mannheim, Germany). The color reaction 
was stopped by washing the membranes with 
distilled water. Cell lysates were detected on a 
separate membrane with beta actin as a loading 
control. 
Statistical analyzes  
All experiments were done in triplicate. Statis- 
tical analyzes were done using nonparametric 
Kruskal-Wallis test. Pairwise comparisons between 
groups were performed by Mann-Whitney test. All 
statistical analyzes were performed with Graph Pad 
Prism5 software. All data were presented as 
mean±SEM and P <0.05 was considered as the 
level of significance. 
 
Results 
First, we examined the effect of oxLDL on 
osteonectin gene expression in VSMCs. Our results 
showed that oxLDL increased osteonectin 
expression 1.62 ± 0.23- and 6.62 ± 0.48-fold after 
24 and 48 hours, respectively compared with the 
control group (P=0.01) (Figures 1A, 2A). Then, we 
examined the effect of adiponectin on osteonectin 
expression in oxLDL-induced VSMCs. Interestin-
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gly, when VSMCs were treated with both oxLDL 
and adiponectin there was an additional effect on 
osteonectin expression (3.24 ± 0.39- and 24.93 ± 
2.15-fold after 24 and 48 hours, respectively) 
(P=0.001) (Figures 1A, 2A). 
The results were confirmed by western blot 
analysis at protein levels. oxLDL alone and 
together with adiponectin increased the osteonectin 
protein level (Figures 1B, 2B). Beta actin (42 kDa) 
was used as an internal control to standardize the 
protein loading in western blotting experiments. 
 
Discussion 
Blood osteonectin concentration correlated 
significantly with atherosclerosis, stenosis and 
calcinosis of coronary arteries (20). In the present 
study, oxLDL increased osteonectin expression in 
VSMCs. Other studies have shown over expression 
of osteopontin and alkaline phosphatase in response 
to oxidative stress (21). 
Adiponectin is involved in atherosclerosis (22, 
23) and the anti-inflammatory effects of this 
adipocytokine have been already demonstrated. 
There are few reports on the preservative effects of 
adiponectin in arterial wall calcification (24, 25) but 
the adverse effects of adiponectin have been 
reported (26, 27). In a study, the relationship 
between adiponectin and coronary heart disease in 
old adults was investigated and the direct correla-
tion between high adiponectin and the risk of 
coronary heart disease was reported (28). 
Our results showed that adiponectin intensi-
fied the oxLDL-induced increase in osteonectin 
level. 
Luo et al. reported that adiponectin increased 
osteoblast cells proliferation and could raise 
alkaline phosphatase, osteocalcin and collagen type 
2 proteins (29). Therefore, the increase in 
osteonectin expression, one of the secreted proteins 
by osteoblast in VSMCs, is not surprising. 
As seen in this experimental study, if a 
synergistic effect exists between adiponectin and 
oxLDL,  adiponectin  may play a role in the intensi- 
fication of vascular calcification. 
An experimental study reported that 
adiponectin would stop alkaline phosphatase 
activity, osteonectin secretion, Runx2 protein 
expression, and mineralization in VMSCs (30). It 
means that adiponectin may act as a factor 
influencing the decrease of proteins involved in 
calcification. The adiponectin density used in that 
study was 30 µg/ mL and its effect lasted for 
approximately 20 days. That study was also 
performed in vivo, which seems to be the reason for 
the findings’ inconsistency. There is no clear and 
definite data about inhibitory or activating effects of 
osteonectin on vascular calcification. If osteonectin 
reduces vascular calcification, adiponectin will 
have preservative effect against calcification and if 
osteonectin exacerbates calcification process, 
adiponectin can enhance calcification and therefore 
is a risk factor, besides the oxLDL, for calcification. 
In conclusion, regarding osteonectin role as an 
activating factor of calcification, oxLDL could act 
as a factor of increasing osteonectin gene 
expression in VSMCs, with adiponectin intensifing 
this process. 
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